<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="other"><?properties open_access?><!-- Original-type: cy--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">16622455</article-id><article-id pub-id-type="pmc">2361413</article-id><article-id pub-id-type="pii">6603095</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6603095</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Studies</subject></subj-group></article-categories><title-group><article-title>A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mabro</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Artru</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Andr&#x000e9;</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Flesch</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Maindrault-Goebel</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Landi</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Lledo</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Plantade</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Louvet</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>de Gramont</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medical Oncology, H&#x000f4;pital Foch, 40 rue Worth, 92151 Suresnes Cedex, France</aff><aff id="aff2"><label>2</label>Department of Medical Oncology, Clinique Saint-Jean, Lyon, France</aff><aff id="aff3"><label>3</label>Department of Medical Oncology, H&#x000f4;pital Tenon, Paris, France</aff><aff id="aff4"><label>4</label>Department of Medicine, H&#x000f4;pital de Dijon, Dijon, France</aff><aff id="aff5"><label>5</label>Department of Medical Oncology, H&#x000f4;pital Saint-Antoine, Paris, France</aff><aff id="aff6"><label>6</label>Department of Medical Oncology, H&#x000f4;pital Europ&#x000e9;en Georges Pompidou, Paris, France</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:m.mabro@hopital-foch.org">m.mabro@hopital-foch.org</email></corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>05</month><year>2006</year></pub-date><pub-date pub-type="ppub"><day>08</day><month>05</month><year>2006</year></pub-date><volume>94</volume><issue>9</issue><fpage>1287</fpage><lpage>1292</lpage><history><date date-type="received"><day>09</day><month>11</month><year>2005</year></date><date date-type="rev-recd"><day>13</day><month>03</month><year>2006</year></date><date date-type="accepted"><day>13</day><month>03</month><year>2006</year></date></history><copyright-statement>Copyright 2006, Cancer Research UK</copyright-statement><copyright-year>2006</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p>In advanced colorectal cancer previously treated with oxaliplatin, efficacy of irinotecan-based chemotherapy is poor and the best regimen is not defined. We designed FOLFIRI-3 and conducted a phase II study to establish its efficacy and safety in advanced colorectal cancer patients previously treated with FOLFOX. FOLFIRI-3 consisted of irinotecan 100&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> as a 60-min infusion on day 1, running concurrently with leucovorin 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> as a 2-h infusion on day 1, followed by 46-h continuous infusion of 5-fluorouracil (5FU) 2000&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, and irinotecan 100&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> repeated on day 3, at the end of the 5FU infusion, every 2 weeks. Sixty-five patients entered the study. The intent-to-treat objective response rate was 23&#x00025; (95&#x00025; CI 13&#x02013;33&#x00025;). Disease was stable in 37&#x00025; of patients, progressed in 26&#x00025; and was not assessable in 14&#x00025;. From the start of FOLFIRI-3, median progression-free survival was 4.7 months and median survival 10.5 months. Main toxicities (&#x00025; of patients) were grade 3&#x02013;4 diarrhoea 23&#x00025; and grade 4 neutropenia 11&#x00025;. FOLFIRI-3 is a promising regimen achieving high response rate and progression-free survival in patients previously treated with FOLFOX with a moderate toxicity.</p></abstract><kwd-group><kwd>colorectal cancer</kwd><kwd>combination chemotherapy</kwd><kwd>irinotecan</kwd><kwd>5-fluorouracil</kwd><kwd>leucovorin</kwd><kwd>phase II study</kwd></kwd-group></article-meta></front><body><p>Colorectal cancer is the one of the commonest cancers worldwide and remains a leading cause of mortality. For many years the main treatment for metastatic colorectal cancer consisted of 5-fluorouracil (5FU) modulated by leucovorin (LV). Since 1990, tremendous progresses have been made through the availability of several new drugs, such as oxaliplatin and irinotecan (<xref ref-type="other" rid="bib2">Cunningham <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib22">Rougier <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib3">De Gramont <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib4">Douillard <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib24">Saltz <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib10">Grothey <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib9">Goldberg <italic>et al</italic>, 2004</xref>).</p><p>Irinotecan has definite activity against advanced metastatic colorectal cancer both in chemotherapy-naive patients and after 5FU failure (<xref ref-type="other" rid="bib2">Cunningham <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib22">Rougier <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib4">Douillard <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib24">Saltz <italic>et al</italic>, 2000</xref>). Two randomised studies in patients with 5FU bolus-resistant metastatic colorectal cancer established the superiority of irinotecan over best supportive care (<xref ref-type="other" rid="bib2">Cunningham <italic>et al</italic>, 1998</xref>) or 5FU continuous-infusion regimens (<xref ref-type="other" rid="bib22">Rougier <italic>et al</italic>, 1998</xref>). Later, two large multicentre randomised studies established the superiority of irinotecan combined with 5FU and LV over 5FU&#x02013;LV as first-line treatment of metastatic colorectal cancer (<xref ref-type="other" rid="bib4">Douillard <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib24">Saltz <italic>et al</italic>, 2000</xref>). Two additional randomised studies demonstrated the superiority of oxaliplatin combined with LV5FU2 (FOLFOX4) over 5FU and LV as front therapy (<xref ref-type="other" rid="bib3">De Gramont <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib10">Grothey <italic>et al</italic>, 2002</xref>). More recently, in a large phase III study, FOLFOX4 achieved better response rate, progression-free survival and overall survival than the irinotecan-based IFL regimen as first-line treatment of metastatic colorectal cancer (<xref ref-type="other" rid="bib9">Goldberg <italic>et al</italic>, 2004</xref>). However, few data are available about irinotecan-based chemotherapy in patients previously treated with FOLFOX. Thus, the FOLFIRI regimen achieved a 5&#x00025; response rate in pretreated patients (<xref ref-type="other" rid="bib1">Andr&#x000e9; <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib27">Tournigand <italic>et al</italic>, 2004</xref>).</p><p><italic>In vitro</italic> studies suggested that the synergy between irinotecan and 5FU is sequence dependent, with a higher cytotoxicity when irinotecan is administered before 5FU (<xref ref-type="other" rid="bib11">Guichard <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib17">Mullany <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib16">Mans <italic>et al</italic>, 1999</xref>). Clinical data are less documented. In a phase II randomised study evaluating the sequence effect of irinotecan and 5FU, toxicities were affected by the sequence of administration, with a worsened tolerability when 5FU was followed by irinotecan (<xref ref-type="other" rid="bib6">Falcone <italic>et al</italic>, 2001</xref>). These results suggested that cytotoxicity is higher when irinotecan is administered after 5FU (<xref ref-type="other" rid="bib6">Falcone <italic>et al</italic>, 2001</xref>). Thus, we previously designed the FOLFIRI-2 regimen consisting of irinotecan 180&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> combined with a simplified LV5FU regimen, with irinotecan administered at the end of the 5FU infusion (<xref ref-type="other" rid="bib13">Mabro <italic>et al</italic>, 2003</xref>). In this phase II study of patients with heavily pretreated colorectal cancer, efficacy was encouraging, with a 17&#x00025; confirmed response rate and 4.1 months progression-free survival, but toxicity was high.</p><p>Thus, irinotecan-based chemotherapy after FOLFOX needs to be improved and the best schedule is not yet established. We designed a new regimen, FOLFIRI-3, in which irinotecan is administered as two infusions: half-dose before 5FU and half-dose at the end of the 5FU infusion, and conducted this multicentre phase II study to evaluate the efficacy of the FOLFIRI-3 regimen in advanced colorectal cancer patients previously treated with FOLFOX regimen.</p><sec sec-type="methods"><title>PATIENTS AND METHODS</title><p>This study was an open multicentre phase II study conducted from June 2001 to December 2002. The study fulfilled the Clinical Good Practice Guidelines and was approved by the Ethics Committee of La Piti&#x000e9; &#x02013; Salp&#x000ea;tri&#x000e8;re Hospital, Paris, France. Written informed consent was obtained from all patients prior to study entry.</p><p>The main end point of the study was progression-free survival. The other study parameters were: response rate, overall survival and toxicity.</p><sec><title>Inclusion criteria</title><p>Patients were required to be 18&#x02013;80 years old, and to have metastatic adenocarcinoma of the colon or the rectum histologically proven and previously treated with a FOLFOX regimen. An interval of at least 2 weeks must have elapsed since prior treatment. Other eligibility criteria were: no central nervous system metastases, WHO performance status 0&#x02013;2, initial evaluation &#x02a7d;2 weeks before inclusion by computed tomography scan prior to initiation of therapy and feasibility of regular follow-up. Required laboratory parameters included: neutrophil count &#x02a7e;1500&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup>, platelet count &#x02a7e;100&#x02009;000&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup>, serum alkaline phosphatase &#x0003c;3 times the upper limit of normal (ULN) and bilirubin &#x0003c;1.5 times ULN.</p></sec><sec><title>Treatment administration</title><p>FOLFIRI-3 regimen was given every 14 days as follows: on day 1, irinotecan 100&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> as a 1-h infusion, running concurrently with LV 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> as a 2-h infusion via a Y-connector, followed by 5FU 2000&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> as a 46-h infusion using a disposable elastomeric pump. On day 3, irinotecan 100&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> as a 1-h infusion was repeated, at the end of the 5FU infusion (<xref ref-type="fig" rid="fig1">Figure 1</xref>). In the absence of grade 2 toxicity after two cycles, the dose of irinotecan was to be increased from 100 to 120&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> at days 1 and 3. Treatment was continued until disease progression or limiting toxicity.</p><p>Blood tests and clinical evaluation were performed every 2 weeks, prior to treatment. Chemotherapy could be administered if neutrophil count was &#x02a7e;1500&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup>, platelet count &#x02a7e;100&#x02009;000&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup> and if clinical toxicity was resolved or &#x0003c;grade 2. In case of grade &#x0003e;2 neutropenia, thrombocytopenia or diarrhoea toxicity, the dose of irinotecan was to be reduced from 100 to 80&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>. If neutropenia, thrombocytopenia or diarrhoea &#x0003e;grade 2 persisted at this latter dose, chemotherapy was discontinued.</p></sec><sec><title>Supportive care</title><p>Specific anti-emetic prophylaxis was left to the investigator's discretion. For patients who experienced an early cholinergic syndrome occurring during or shortly after irinotecan administration, atropine sulphate (0.25&#x02009;mg) could be given subcutaneously. The use of loperamide was recommended in case of diarrhoea.</p></sec><sec><title>Study parameters</title><p>Before each cycle, patients underwent a clinical examination, and blood cells were counted. All toxicities were reported according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) (<xref ref-type="other" rid="bib14">MacDonald <italic>et al</italic>, 1995</xref>). Carcinoembryogenic antigen, bilirubin, serum alkaline phosphatases, serum creatinine, lactate dehydrogenase, chest X-ray and CT scans were repeated every 8 weeks (i.e. every four cycles) or earlier in the case of worsening of clinical condition. Tumour response was assessed by RECIST criteria (<xref ref-type="other" rid="bib26">Therasse <italic>et al</italic>, 2000</xref>). Tumour growth control was defined by the proportion of patients with response rate or stable disease.</p></sec><sec><title>Statistical considerations</title><p>Based on previous studies, we expected FOLFIRI-3 to achieve a 40&#x00025; rate of nonprogressive patients at 6 months. According to a binomial distribution point estimate of proportion, with 5&#x00025; significance and 80&#x00025; power, 65 patients were to be enrolled. Survival times were calculated from the start of FOLFIRI-3 until death. Time to progression was calculated from the first day of FOLFIRI-3 to the date of progression for all the patients entering the study. Survival curves were obtained using the Kaplan&#x02013;Meier method (<xref ref-type="other" rid="bib12">Kaplan and Meier, 1958</xref>).</p></sec></sec><sec><title>RESULTS</title><p>From 17 June 2001 to 19 December 2002, 65 patients were recruited from nine French institutions. Their characteristics are described in <xref rid="tbl1" ref-type="table">Table 1</xref>. All patients had previously been treated with a FOLFOX regimen (combination of oxaliplatin, infusion 5FU and LV), and had experienced disease progression while on FOLFOX (36 patients) or after discontinuation (29 patients). Thirteen patients (20&#x00025;) had previously been treated with at least two regimens for metastatic purpose before entering the FOLFIRI-3 study.</p><sec><title>Treatment</title><p>The median number of treatment cycles administered was 7 (range, 1&#x02013;20). Six patients (9&#x00025;) refused to continue after the first or the second course (personal convenience without toxicity &#x0003e;grade 2). In six patients (9&#x00025;) treatment was stopped because of grade 3 or 4 toxicity. Tumour response was not assessable in nine of those 12 patients. In 39 patients (60&#x00025;) treatment was stopped because of disease progression after a median of eight courses. In 14 additional patients (21&#x00025;) chemotherapy was interrupted by investigator after 8&#x02013;20 cycles, without evidence of disease progression nor severe toxicity.</p><p>Dose reductions occurred in 25 patients due to grade 3 toxicities, mainly vomiting, diarrhoea or mucositis. Irinotecan dose was increased according to the design of the study only in 12 patients with a median dose level of 120&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> on days 1 and 3. Grade 3 toxicity occurred only in one of these patients.</p></sec><sec><title>Safety</title><p>Side effects were collected for 463 cycles according to the NCI-CTC grade scale. Toxicities are listed in <xref rid="tbl2" ref-type="table">Table 2</xref>. Neutropenia reached grade 3&#x0002f;4 in 37&#x00025; of patients, including three patients (5&#x00025;) who had one episode of febrile neutropenia. There was one toxic death after the first course of chemotherapy related to a sepsis shock with neutropenia and diarrhoea. Overall, 10 patients (15&#x00025;) experienced at least one grade 4 toxicity and 20 patients (31&#x00025;) experienced one grade 3 nonhematological toxicity.</p></sec><sec><title>Survival and objective response</title><p>Progression free survival for 6 months was 42&#x00025;. From the start of FOLFIRI-3, median progression-free survival was 20.5 weeks (4.7 months) and median survival was 46 weeks (10.5 months). Survival curves are shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p><p>Tumour response was assessable in 56 patients and not assessable in nine patients (14&#x00025;). Response rates were calculated in the intent-to-treat population. Objective response was obtained in 15 patients (1 complete, 14 partial), achieving a 23&#x00025; (95&#x00025; CI 13&#x02013;33&#x00025;) response rate (15 out of 65). The number of responder patients assessed by RECIST criteria are listed in <xref rid="tbl3" ref-type="table">Table 3</xref>. Disease was stable in 24 patients (37&#x00025;) and progressed in 17 (26&#x00025;). Tumour growth control was 60&#x00025; (95&#x00025; CI 48&#x02013;72&#x00025;).</p><p>Regarding assessable patients, response rate was 27&#x00025; (95&#x00025; CI 15&#x02013;39&#x00025;), and 22&#x00025; in the subset of patients in whom disease progressed while on previous FOLFOX regimen, and 33&#x00025; in the subset of patients in whom disease progressed after FOLFOX discontinuation.</p></sec></sec><sec><title>DISCUSSION</title><p>This multicentre phase II study assessed the efficacy and tolerability of the FOLFIRI-3 regimen, a new combination of irinotecan and LV5FU, in patients with metastatic colorectal cancer previously treated with FOLFOX. With 42&#x00025; of patients free of progression at 6 months, the main objective of the study was reached.</p><p>Several phase II studies (<xref ref-type="other" rid="bib18">Pitot <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib20">Rougier <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib19">Rothenberg <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib28">Van Cutsem <italic>et al</italic>, 1999</xref>) and two large phase III studies (<xref ref-type="other" rid="bib2">Cunningham <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib22">Rougier <italic>et al</italic>, 1998</xref>) established the efficacy of irinotecan after 5FU failure (<xref rid="tbl4" ref-type="table">Table 4</xref>). In phase II studies of irinotecan alone, after 5FU failure response rates were 11&#x02013;16&#x00025; (<xref ref-type="other" rid="bib20">Rougier <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib19">Rothenberg <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib28">Van Cutsem <italic>et al</italic>, 1999</xref>), and progression-free survival was 3&#x02013;4 months (<xref ref-type="other" rid="bib18">Pitot <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib20">Rougier <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib19">Rothenberg <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib28">Van Cutsem <italic>et al</italic>, 1999</xref>). In phase III studies of irinotecan after 5FU failure, progression-free survival was 3&#x02013;4 months (<xref ref-type="other" rid="bib2">Cunningham <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib22">Rougier <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib7">Fuchs <italic>et al</italic>, 2003</xref>). Response rate was reported in only one of those studies and was 4.5&#x00025; (<xref ref-type="other" rid="bib22">Rougier <italic>et al</italic>, 1998</xref>).</p><p>The combination of irinotecan with 5FU and LV after 5FU failure was evaluated in three phase II studies. Reported response rates were 11.4&#x02013;21&#x00025; (<xref ref-type="other" rid="bib5">Ducreux <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib8">Gil-Delgado <italic>et al</italic>, 2001</xref>; <xref ref-type="other" rid="bib21">Rougier <italic>et al</italic>, 2002</xref>). As shown in <xref rid="tbl4" ref-type="table">Table 4</xref>, results observed with regimens combining irinotecan, 5FU and LV after 5FU failure seem slightly better than those with irinotecan alone, in a cross-study comparison. More recently, a large randomised phase III study was conducted enrolling more than 2000 patients. In this study, the addition of irinotecan to 5FU after 5FU failure achieved better survival (14.8 <italic>vs</italic> 13.9 months from the start of front-line 5FU) and higher response rate (21 <italic>vs</italic> 11&#x00025;) than irinotecan alone after 5FU failure (<xref ref-type="other" rid="bib25">Seymour <italic>et al</italic>, 2005</xref>). These results encourage the administration of 5FU with irinotecan despite previous 5FU failure.</p><p>Efficacy of irinotecan in patients previously treated with FOLFOX is less documented. Results of the FOLFIRI, FOLFIRI-2 and FOLFIRI-3 studies are summarised in <xref rid="tbl4" ref-type="table">Table 4</xref>. In a randomised trial recently reported, irinotecan alone achieved a 4&#x00025; response rate and 2.7 progression-free survival in 94 patients previously treated with 5FU as front line and FOLFOX4 as second line (<xref ref-type="other" rid="bib23">Rowland <italic>et al</italic>, 2005</xref>).</p><p>In the present study, the progression-free survival was 4.7 months and the intent-to-treat response rate was 23&#x00025;, higher than those reported with irinotecan alone, FOLFIRI and FOLFIRI-2 after FOLFOX. In a cross-study comparison, efficacy of FOLFIRI-3 seems slightly better than FOLFIRI-2, as FOLFIRI-2 showed a high toxicity profile. The main FOLFIRI-2 grade 3&#x02013;4 toxicities were diarrhoea (31&#x00025;), neutropenia (52&#x00025;), and febrile neutropenia (14&#x00025;) (<xref ref-type="other" rid="bib13">Mabro <italic>et al</italic>, 2003</xref>). Toxicity of FOLFIRI-3 was moderate, lower than FOLFIRI-2 study and quite higher than FOLFIRI in pretreated patients (<xref ref-type="other" rid="bib1">Andr&#x000e9; <italic>et al</italic>, 1999</xref>). It is difficult to assess if this increased toxicity is related to the divided dose of irinotecan or to the total dose of irinotecan, which is 10&#x00025; more than in the FOLFIRI (200 instead of 180&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> per cycle). Differences should be also partly due to the subset of patients. In particular, patients of the FOLFIRI-3 study were less selected and 17&#x00025; entered the study with a PS 2.</p><p>In conclusion, FOLFIRI-3 is a feasible regimen with encouraging response rate and progression-free survival in patients previously treated with FOLFOX. Future studies should evaluate the combination of FOLFIRI-3 with molecular targeted therapies like bevacizumab, cetuximab or new oral anti-REGF molecules.</p></sec></body><back><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andr&#x000e9;</surname><given-names>T</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Maindrault-Goebel</surname><given-names>F</given-names></name><name><surname>Couteau</surname><given-names>C</given-names></name><name><surname>Mabro</surname><given-names>M</given-names></name><name><surname>Lotz</surname><given-names>JP</given-names></name><name><surname>Gilles-Amar</surname><given-names>V</given-names></name><name><surname>Krulik</surname><given-names>M</given-names></name><name><surname>Carola</surname><given-names>E</given-names></name><name><surname>Izrael</surname><given-names>V</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name></person-group><article-title>CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer</article-title><source>Eur J Cancer</source><year>1999</year><volume>35</volume><fpage>1343</fpage><lpage>1347</lpage><!--PubMed citation query: 'Eur J Cancer||35|1343||bib1|'--><pub-id pub-id-type="pmid">10658525</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Pyrh&#x000f6;nen</surname><given-names>S</given-names></name><name><surname>James</surname><given-names>RD</given-names></name><name><surname>Punt</surname><given-names>CJ</given-names></name><name><surname>Hickish</surname><given-names>TF</given-names></name><name><surname>Heikkila</surname><given-names>R</given-names></name><name><surname>Johannesen</surname><given-names>TB</given-names></name><name><surname>Starkhammar</surname><given-names>H</given-names></name><name><surname>Topham</surname><given-names>CA</given-names></name><name><surname>Awad</surname><given-names>L</given-names></name><name><surname>Jacques</surname><given-names>C</given-names></name><name><surname>Herait</surname><given-names>P</given-names></name></person-group><article-title>Randomised trial of irinotecan plus supportive care <italic>vs</italic> supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>1413</fpage><lpage>1418</lpage><!--PubMed citation query: 'Lancet||352|1413||bib2|'--><pub-id pub-id-type="pmid">9807987</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Gramont</surname><given-names>A</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Seymour</surname><given-names>M</given-names></name><name><surname>Homerin</surname><given-names>M</given-names></name><name><surname>Hmissi</surname><given-names>A</given-names></name><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Cortes-Funes</surname><given-names>H</given-names></name><name><surname>Cervantes</surname><given-names>A</given-names></name><name><surname>Freyer</surname><given-names>G</given-names></name><name><surname>Papamichael</surname><given-names>D</given-names></name><name><surname>Le Bail</surname><given-names>N</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Hendler</surname><given-names>D</given-names></name><name><surname>de Braud</surname><given-names>F</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Morvan</surname><given-names>F</given-names></name><name><surname>Bonetti</surname><given-names>A</given-names></name></person-group><article-title>Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>2938</fpage><lpage>2947</lpage><!--PubMed citation query: 'J Clin Oncol||18|2938||bib3|'--><pub-id pub-id-type="pmid">10944126</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Roth</surname><given-names>AD</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>James</surname><given-names>RD</given-names></name><name><surname>Karasek</surname><given-names>P</given-names></name><name><surname>Jandik</surname><given-names>P</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Carmichael</surname><given-names>J</given-names></name><name><surname>Alakl</surname><given-names>M</given-names></name><name><surname>Gruia</surname><given-names>G</given-names></name><name><surname>Awad</surname><given-names>L</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name></person-group><article-title>Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>1041</fpage><lpage>1047</lpage><!--PubMed citation query: 'Lancet||355|1041||bib4|'--><pub-id pub-id-type="pmid">10744089</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ducreux</surname><given-names>M</given-names></name><name><surname>Ychou</surname><given-names>M</given-names></name><name><surname>Seitz</surname><given-names>JF</given-names></name><name><surname>Bonnay</surname><given-names>M</given-names></name><name><surname>Bexon</surname><given-names>A</given-names></name><name><surname>Armand</surname><given-names>JP</given-names></name><name><surname>Mahjoubi</surname><given-names>M</given-names></name><name><surname>Mery-Mignard</surname><given-names>D</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name></person-group><article-title>Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>2901</fpage><lpage>2908</lpage><!--PubMed citation query: 'J Clin Oncol||17|2901||bib5|'--><pub-id pub-id-type="pmid">10561369</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Falcone</surname><given-names>A</given-names></name><name><surname>di Paolo</surname><given-names>A</given-names></name><name><surname>Masi</surname><given-names>G</given-names></name><name><surname>Allegrini</surname><given-names>G</given-names></name><name><surname>Danesi</surname><given-names>R</given-names></name><name><surname>Lencioni</surname><given-names>M</given-names></name><name><surname>Pfanner</surname><given-names>E</given-names></name><name><surname>Comis</surname><given-names>S</given-names></name><name><surname>Del Tacca</surname><given-names>M</given-names></name><name><surname>Conte</surname><given-names>P</given-names></name></person-group><article-title>Sequence effect of irinotecan on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients</article-title><source>J Clin Oncol</source><year>2001</year><volume>19</volume><fpage>3456</fpage><lpage>3462</lpage><!--PubMed citation query: 'J Clin Oncol||19|3456||bib6|'--><pub-id pub-id-type="pmid">11481350</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>CS</given-names></name><name><surname>Moore</surname><given-names>MR</given-names></name><name><surname>Harker</surname><given-names>G</given-names></name><name><surname>Villa</surname><given-names>L</given-names></name><name><surname>Rinaldi</surname><given-names>D</given-names></name><name><surname>Hecht</surname><given-names>J</given-names></name></person-group><article-title>Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>807</fpage><lpage>814</lpage><!--PubMed citation query: 'J Clin Oncol||21|807||bib7|'--><pub-id pub-id-type="pmid">12610178</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gil-Delgado</surname><given-names>MA</given-names></name><name><surname>Guinet</surname><given-names>F</given-names></name><name><surname>Castaing</surname><given-names>D</given-names></name><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Coeffic</surname><given-names>D</given-names></name><name><surname>Durrani</surname><given-names>AK</given-names></name><name><surname>Bismuth</surname><given-names>H</given-names></name><name><surname>Khayat</surname><given-names>D</given-names></name></person-group><article-title>Prospective phase II trial of irinotecan, 5-fluorouacil, and leucovorin in combination as salvage therapy for advanced colorectal cancer</article-title><source>Am J Clin Oncol</source><year>2001</year><volume>24</volume><fpage>101</fpage><lpage>105</lpage><!--PubMed citation query: 'Am J Clin Oncol||24|101||bib8|'--><pub-id pub-id-type="pmid">11232943</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>RM</given-names></name><name><surname>Sargent</surname><given-names>DJ</given-names></name><name><surname>Morton</surname><given-names>RF</given-names></name><name><surname>Fuchs</surname><given-names>CS</given-names></name><name><surname>Ramanathan</surname><given-names>RK</given-names></name><name><surname>Williamson</surname><given-names>SK</given-names></name><name><surname>Findlay</surname><given-names>BP</given-names></name><name><surname>Pitot</surname><given-names>HC</given-names></name><name><surname>Alberts</surname><given-names>SR</given-names></name></person-group><article-title>A randomised controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>4</fpage><lpage>6</lpage><!--PubMed citation query: 'J Clin Oncol||22|4||bib9|'--><pub-id pub-id-type="pmid">14665617</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grothey</surname><given-names>A</given-names></name><name><surname>Deschler</surname><given-names>B</given-names></name><name><surname>Kroening</surname><given-names>H</given-names></name><name><surname>Ridwelski</surname><given-names>K</given-names></name><name><surname>Reichardt</surname><given-names>P</given-names></name><name><surname>Kretzschmar</surname><given-names>A</given-names></name><name><surname>Clemens</surname><given-names>M</given-names></name><name><surname>Hirschmann</surname><given-names>W</given-names></name><name><surname>Lorenz</surname><given-names>M</given-names></name><name><surname>Asperger</surname><given-names>W</given-names></name><name><surname>Buechele</surname><given-names>T</given-names></name><name><surname>Schmoll</surname><given-names>HJ</given-names></name></person-group><article-title>Phase III study of bolus 5-fluorouracil (5FU)&#x0002f;folinic acid (FA) (Mayo) <italic>vs</italic> weekly high-dose 24&#x02009;h 5-FU infusion&#x0002f;FA&#x0002b;oxaliplatin (OXA) in advanced colorectal cancer (ACRC)</article-title><source>Proc Am Soc Clin Oncol (Orlando, FL, USA)</source><year>2002</year><volume>21</volume><fpage>129a</fpage>(abstract)<!--PubMed citation query: 'Proc Am Soc Clin Oncol (Orlando, FL, USA)||21|129a||bib10|'--></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guichard</surname><given-names>S</given-names></name><name><surname>Cussac</surname><given-names>D</given-names></name><name><surname>Hennebelle</surname><given-names>I</given-names></name><name><surname>Bugat</surname><given-names>R</given-names></name><name><surname>Canal</surname><given-names>P</given-names></name></person-group><article-title>Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source>Int J Cancer</source><year>1997</year><volume>73</volume><fpage>729</fpage><lpage>734</lpage><!--PubMed citation query: 'Int J Cancer||73|729||bib11|'--><pub-id pub-id-type="pmid">9398054</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>EL</given-names></name><name><surname>Meier</surname><given-names>P</given-names></name></person-group><article-title>Nonparametric estimation from incomplete observations</article-title><source>J Am Stat Assoc</source><year>1958</year><volume>53</volume><fpage>457</fpage><lpage>481</lpage><!--PubMed citation query: 'J Am Stat Assoc||53|457||bib12|'--></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mabro</surname><given-names>M</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>T</given-names></name><name><surname>Carola</surname><given-names>E</given-names></name><name><surname>Gilles-Amar</surname><given-names>V</given-names></name><name><surname>Artru</surname><given-names>P</given-names></name><name><surname>Krulik</surname><given-names>M</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name><name><surname>on behalf</surname><given-names>GERCOR</given-names></name></person-group><article-title>Bimonthly leucovorin, infusion, 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer</article-title><source>Am J Clin Oncol</source><year>2003</year><volume>25</volume><fpage>254</fpage><lpage>258</lpage><!--PubMed citation query: 'Am J Clin Oncol||25|254||bib13|'--></citation></ref><ref id="bib14"><citation citation-type="book"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>J</given-names></name><name><surname>Haller</surname><given-names>D</given-names></name><name><surname>Mayer</surname><given-names>R</given-names></name></person-group><article-title>Grading of toxicity</article-title><source>Manual of Oncologic Therapeutics</source><year>1995</year><publisher-name>Lippincott: Philadelphia</publisher-name><fpage>519</fpage><lpage>523</lpage>MacDonald J, Haller D, Mayer R (eds) pp</citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maindrault</surname><given-names>F</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Tournigand</surname><given-names>C</given-names></name><name><surname>Gervais</surname><given-names>H</given-names></name><name><surname>Mabro</surname><given-names>M</given-names></name><name><surname>Artru</surname><given-names>P</given-names></name><name><surname>Garcia</surname><given-names>ML</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>T</given-names></name><name><surname>Carola</surname><given-names>C</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name></person-group><article-title>Leucovorin, 5-fluorouracil infusion and irinotecan (FOLFIRI-3) in pretreated patients with metastatic colorectal cancer</article-title><source>Proc Am Soc Clin Oncol (Orlando, FL, USA)</source><year>2002</year><volume>21</volume><fpage>658a</fpage>abstract<!--PubMed citation query: 'Proc Am Soc Clin Oncol (Orlando, FL, USA)||21|658a||bib15|'--></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mans</surname><given-names>DRA</given-names></name><name><surname>Grivicich</surname><given-names>I</given-names></name><name><surname>Peters</surname><given-names>GJ</given-names></name><name><surname>Schwartsmann</surname><given-names>G</given-names></name></person-group><article-title>Sequence-dependent growth inhibition and DNA damage by the irinotecan&#x02013;5-fluorouracil combination in human colon carcinoma cell lines</article-title><source>Eur J Cancer</source><year>1999</year><volume>35</volume><fpage>1851</fpage><lpage>1861</lpage><!--PubMed citation query: 'Eur J Cancer||35|1851||bib16|'--><pub-id pub-id-type="pmid">10674003</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mullany</surname><given-names>S</given-names></name><name><surname>Svingen</surname><given-names>PA</given-names></name><name><surname>Kaufmann</surname><given-names>SH</given-names></name><name><surname>Erlichman</surname><given-names>C</given-names></name></person-group><article-title>Effect of adding the topoisomerase I poison 7-ethyl 10-hydroxycamptothecin (SN 38) to 5-fluorouracil and folinic acid in HCT8 cells: elevated dTTP pools and enhanced cytotoxicity</article-title><source>Cancer Chemother Pharm</source><year>1998</year><volume>42</volume><fpage>391</fpage><lpage>399</lpage><!--PubMed citation query: 'Cancer Chemother Pharm||42|391||bib17|'--></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pitot</surname><given-names>HC</given-names></name><name><surname>Wender</surname><given-names>DB</given-names></name><name><surname>O'Connell</surname><given-names>MJ</given-names></name><name><surname>Schroeder</surname><given-names>G</given-names></name><name><surname>Goldberg</surname><given-names>RM</given-names></name><name><surname>Rubin</surname><given-names>J</given-names></name><name><surname>Mailliard</surname><given-names>JA</given-names></name><name><surname>Knost</surname><given-names>JA</given-names></name><name><surname>Ghosh</surname><given-names>C</given-names></name><name><surname>Kirschling</surname><given-names>RJ</given-names></name><name><surname>Levitt</surname><given-names>R</given-names></name><name><surname>Windschitl</surname><given-names>HE</given-names></name></person-group><article-title>Phase II trial of irinotecan in patients with metastatic colorectal carcinoma</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>2910</fpage><lpage>2919</lpage><!--PubMed citation query: 'J Clin Oncol||15|2910||bib18|'--><pub-id pub-id-type="pmid">9256135</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rothenberg</surname><given-names>ML</given-names></name><name><surname>Cox</surname><given-names>JV</given-names></name><name><surname>DeVore</surname><given-names>RF</given-names></name><name><surname>Hainsworth</surname><given-names>JD</given-names></name><name><surname>Pazdur</surname><given-names>R</given-names></name><name><surname>Rivkin</surname><given-names>SE</given-names></name><name><surname>Macdonald</surname><given-names>JS</given-names></name><name><surname>Geyer</surname><given-names>CE</given-names><suffix>Jr</suffix></name><name><surname>Sandbach</surname><given-names>J</given-names></name><name><surname>Wolf</surname><given-names>DL</given-names></name><name><surname>Mohrland</surname><given-names>JS</given-names></name><name><surname>Elfring</surname><given-names>GL</given-names></name><name><surname>Miller</surname><given-names>LL</given-names></name><name><surname>Von Hoff</surname><given-names>DD</given-names></name></person-group><article-title>A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma</article-title><source>Cancer</source><year>1999</year><volume>85</volume><fpage>786</fpage><lpage>795</lpage><!--PubMed citation query: 'Cancer||85|786||bib19|'--><pub-id pub-id-type="pmid">10091755</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Bugat</surname><given-names>R</given-names></name><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Culine</surname><given-names>S</given-names></name><name><surname>Suc</surname><given-names>E</given-names></name><name><surname>Brunet</surname><given-names>P</given-names></name><name><surname>Becouarn</surname><given-names>Y</given-names></name><name><surname>Ychou</surname><given-names>M</given-names></name><name><surname>Marty</surname><given-names>M</given-names></name><name><surname>Extra</surname><given-names>JM</given-names></name><name><surname>Bonneterre</surname><given-names>J</given-names></name><name><surname>Adenis</surname><given-names>A</given-names></name><name><surname>Seitz</surname><given-names>JF</given-names></name><name><surname>Ganem</surname><given-names>G</given-names></name><name><surname>Namer</surname><given-names>M</given-names></name><name><surname>Conroy</surname><given-names>T</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Merrouche</surname><given-names>Y</given-names></name><name><surname>Burki</surname><given-names>F</given-names></name><name><surname>Mousseau</surname><given-names>M</given-names></name><name><surname>Herait</surname><given-names>P</given-names></name><name><surname>Mahjoubi</surname><given-names>M</given-names></name></person-group><article-title>Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy naive patients and patients pretreated with fluorouracil based chemotherapy</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>251</fpage><lpage>260</lpage><!--PubMed citation query: 'J Clin Oncol||15|251||bib20|'--><pub-id pub-id-type="pmid">8996150</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Lepille</surname><given-names>D</given-names></name><name><surname>Bennouna</surname><given-names>J</given-names></name><name><surname>Marre</surname><given-names>A</given-names></name><name><surname>Ducreux</surname><given-names>M</given-names></name><name><surname>Mignot</surname><given-names>L</given-names></name><name><surname>Hua</surname><given-names>A</given-names></name><name><surname>Mery-Mignard</surname><given-names>D</given-names></name></person-group><article-title>Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study</article-title><source>Ann Oncol</source><year>2002</year><volume>13</volume><fpage>1558</fpage><lpage>1567</lpage><!--PubMed citation query: 'Ann Oncol||13|1558||bib21|'--><pub-id pub-id-type="pmid">12377643</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Bajetta</surname><given-names>E</given-names></name><name><surname>Niederle</surname><given-names>N</given-names></name><name><surname>Possinger</surname><given-names>K</given-names></name><name><surname>Labianca</surname><given-names>R</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>Morant</surname><given-names>R</given-names></name><name><surname>Bleiberg</surname><given-names>H</given-names></name><name><surname>Wils</surname><given-names>J</given-names></name><name><surname>Awad</surname><given-names>L</given-names></name><name><surname>Herait</surname><given-names>P</given-names></name><name><surname>Jacques</surname><given-names>C</given-names></name></person-group><article-title>Randomised trial of irinotecan <italic>vs</italic> fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>1407</fpage><lpage>1412</lpage><!--PubMed citation query: 'Lancet||352|1407||bib22|'--><pub-id pub-id-type="pmid">9807986</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rowland</surname><given-names>KM</given-names></name><name><surname>Pitot</surname><given-names>HC</given-names></name><name><surname>Sargent</surname><given-names>DJ</given-names></name><name><surname>Philip</surname><given-names>PA</given-names></name><name><surname>Mitchell</surname><given-names>EP</given-names></name><name><surname>Mailliard</surname><given-names>JA</given-names></name><name><surname>Goldberg</surname><given-names>RM</given-names></name><name><surname>Alberts</surname><given-names>SR</given-names></name></person-group><article-title>Results of third line therapy on N9841: a randomized phase III trial of oxaliplatin&#x0002f;5-fluorouracil&#x0002f;leucovorin (FOLFOX4) <italic>vs</italic> irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with prior 5FU chemotherapy</article-title><source>Proc Am Soc Clin Oncol (Orlando, FL, USA)</source><year>2005</year><volume>24</volume><fpage>3519a</fpage>abstract<!--PubMed citation query: 'Proc Am Soc Clin Oncol (Orlando, FL, USA)||24|3519a||bib23|'--></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saltz</surname><given-names>LB</given-names></name><name><surname>Cox</surname><given-names>JV</given-names></name><name><surname>Blanke</surname><given-names>C</given-names></name><name><surname>Rosen</surname><given-names>LS</given-names></name><name><surname>Fehrenbacher</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Maroun</surname><given-names>JA</given-names></name><name><surname>Ackland</surname><given-names>SP</given-names></name><name><surname>Locker</surname><given-names>PK</given-names></name><name><surname>Pirotta</surname><given-names>N</given-names></name><name><surname>Elfring</surname><given-names>GL</given-names></name><name><surname>Miller</surname><given-names>LL</given-names></name></person-group><article-title>Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>905</fpage><lpage>914</lpage><!--PubMed citation query: 'N Engl J Med||343|905||bib24|'--><pub-id pub-id-type="pmid">11006366</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seymour</surname><given-names>MT</given-names></name><collab>for the UK NCRI Colorectal Clinical Studies Group and FOCUS Trial Investigators</collab></person-group><article-title>Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): a 2135-patient randomized trial in advanced colorectal cancer (ACRC)</article-title><source>Proc Am Soc Clin Oncol (Orlando, FL, USA)</source><year>2005</year><volume>24</volume><fpage>3518a</fpage>abstract<!--PubMed citation query: 'Proc Am Soc Clin Oncol (Orlando, FL, USA)||24|3518a||bib25|'--></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Arbuck</surname><given-names>SG</given-names></name><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><name><surname>Wanders</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>RS</given-names></name><name><surname>Rubinstein</surname><given-names>L</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>Van Glabbeke</surname><given-names>M</given-names></name><name><surname>van Oosterom</surname><given-names>AT</given-names></name><name><surname>Christian</surname><given-names>MC</given-names></name><name><surname>Gwyther</surname><given-names>SG</given-names></name></person-group><article-title>New guidelines to establish response to treatment in solid tumors</article-title><source>J Nat Cancer Inst</source><year>2000</year><volume>92</volume><fpage>205</fpage><lpage>216</lpage><!--PubMed citation query: 'J Nat Cancer Inst||92|205||bib26|'--></citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tournigand</surname><given-names>C</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>T</given-names></name><name><surname>Achille</surname><given-names>E</given-names></name><name><surname>Lledo</surname><given-names>G</given-names></name><name><surname>Flesh</surname><given-names>M</given-names></name><name><surname>Mery-Mignard</surname><given-names>D</given-names></name><name><surname>Quinaux</surname><given-names>E</given-names></name><name><surname>Couteau</surname><given-names>C</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name><name><surname>Ganem</surname><given-names>G</given-names></name><name><surname>Landi</surname><given-names>B</given-names></name><name><surname>Colin</surname><given-names>P</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name></person-group><article-title>FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>229</fpage><lpage>237</lpage><!--PubMed citation query: 'J Clin Oncol||22|229||bib27|'--><pub-id pub-id-type="pmid">14657227</pub-id></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Ten Bokkel Huinink</surname><given-names>WW</given-names></name><name><surname>Punt</surname><given-names>CJ</given-names></name><name><surname>Alexopoulos</surname><given-names>CG</given-names></name><name><surname>Dirix</surname><given-names>L</given-names></name><name><surname>Symann</surname><given-names>M</given-names></name><name><surname>Blijham</surname><given-names>GH</given-names></name><name><surname>Cholet</surname><given-names>P</given-names></name><name><surname>Fillet</surname><given-names>G</given-names></name><name><surname>Van Groeningen</surname><given-names>C</given-names></name><name><surname>Vannetzel</surname><given-names>JM</given-names></name><name><surname>Levi</surname><given-names>F</given-names></name><name><surname>Panagos</surname><given-names>G</given-names></name><name><surname>Unger</surname><given-names>C</given-names></name><name><surname>Wils</surname><given-names>J</given-names></name><name><surname>Cote</surname><given-names>C</given-names></name><name><surname>Blanc</surname><given-names>C</given-names></name><name><surname>Herait</surname><given-names>P</given-names></name><name><surname>Bleiberg</surname><given-names>H</given-names></name></person-group><article-title>Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)</article-title><source>Eur J Cancer</source><year>1999</year><volume>35</volume><fpage>54</fpage><lpage>59</lpage><!--PubMed citation query: 'Eur J Cancer||35|54||bib28|'--><pub-id pub-id-type="pmid">10211088</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig id="fig1"><label>Figure 1</label><caption><p>Design of FOLFIRI (<xref ref-type="other" rid="bib1">Andr&#x000e9; <italic>et al</italic>, 1999</xref>), FOLFIRI-2 (<xref ref-type="other" rid="bib13">Mabro <italic>et al</italic>, 2003</xref>) and FOLFIRI-3 regimens; cycles are repeated every 2 weeks.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="jpeg" xlink:href="94-6603095f1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>Progression-free survival and overall survival in the FOLFIRI-3 study (65 patients).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="jpeg" xlink:href="94-6603095f2"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Patient characteristics (<italic>n</italic>&#x0003d;65)</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="left" valign="top" charoff="50"><bold><italic>N</italic></bold></th><th align="left" valign="top" charoff="50"><bold>&#x00025;</bold></th></tr><tr><th colspan="3" align="left" valign="top" charoff="50">Median age: 60 years (range: 30&#x02013;79)</th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="left" valign="top" charoff="50">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><italic>Gender</italic></td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male</td><td align="left" valign="top" charoff="50">32</td><td align="left" valign="top" charoff="50">49</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female</td><td align="left" valign="top" charoff="50">33</td><td align="left" valign="top" charoff="50">51</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>WHO performance status</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0</td><td align="left" valign="top" charoff="50">32</td><td align="left" valign="top" charoff="50">49</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="left" valign="top" charoff="50">22</td><td align="left" valign="top" charoff="50">34</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="left" valign="top" charoff="50">11</td><td align="left" valign="top" charoff="50">17</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Primary tumour</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Colon</td><td align="left" valign="top" charoff="50">49</td><td align="left" valign="top" charoff="50">75</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Rectum</td><td align="left" valign="top" charoff="50">16</td><td align="left" valign="top" charoff="50">25</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Site of metastases</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Liver</td><td align="left" valign="top" charoff="50">52</td><td align="left" valign="top" charoff="50">80</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Lung</td><td align="left" valign="top" charoff="50">23</td><td align="left" valign="top" charoff="50">35</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Peritoneum</td><td align="left" valign="top" charoff="50">9</td><td align="left" valign="top" charoff="50">14</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Nodes</td><td align="left" valign="top" charoff="50">11</td><td align="left" valign="top" charoff="50">17</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Other</td><td align="left" valign="top" charoff="50">6</td><td align="left" valign="top" charoff="50">9</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Involved sites</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="left" valign="top" charoff="50">36</td><td align="left" valign="top" charoff="50">55</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="left" valign="top" charoff="50">23</td><td align="left" valign="top" charoff="50">35</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;2</td><td align="left" valign="top" charoff="50">6</td><td align="left" valign="top" charoff="50">9</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Prior adjuvant chemotherapy:</italic></td><td align="left" valign="top" charoff="50">13</td><td align="left" valign="top" charoff="50">20</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;LV5FU</td><td align="left" valign="top" charoff="50">11</td><td align="left" valign="top" charoff="50">17</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;FOLFOX</td><td align="left" valign="top" charoff="50">2</td><td align="left" valign="top" charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Number of lines for metastatic purpose received before FOLFIRI-3</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1 line only</td><td align="left" valign="top" charoff="50">52</td><td align="left" valign="top" charoff="50">80</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2 lines or more</td><td align="left" valign="top" charoff="50">13</td><td align="left" valign="top" charoff="50">20</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>FOLFOX regimen received before FOLFIRI-3</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;FOLFOX7</td><td align="left" valign="top" charoff="50">27</td><td align="left" valign="top" charoff="50">42</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;FOLFOX6</td><td align="left" valign="top" charoff="50">13</td><td align="left" valign="top" charoff="50">20</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;FOLFOX4</td><td align="left" valign="top" charoff="50">25</td><td align="left" valign="top" charoff="50">38</td></tr></tbody></table></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Toxicity of FOLFIRI-3 according to NCI-CTC grading (maximal grade per patient, collected from 463 cycles, 65 patients)</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="4" align="center" valign="top" char="." charoff="50"><bold>NCI-CTC grade (&#x00025; of patients)</bold></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" char="." charoff="50"><bold>1</bold></th><th align="center" valign="top" char="." charoff="50"><bold>2</bold></th><th align="center" valign="top" char="." charoff="50"><bold>3</bold></th><th align="center" valign="top" char="." charoff="50"><bold>4</bold></th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Nonhaematological toxicities</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Nausea</td><td align="char" valign="top" char="." charoff="50">28</td><td align="char" valign="top" char="." charoff="50">29</td><td align="char" valign="top" char="." charoff="50">9</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Vomiting</td><td align="char" valign="top" char="." charoff="50">12</td><td align="char" valign="top" char="." charoff="50">19</td><td align="char" valign="top" char="." charoff="50">8</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Mucositis</td><td align="char" valign="top" char="." charoff="50">20</td><td align="char" valign="top" char="." charoff="50">19</td><td align="char" valign="top" char="." charoff="50">5</td><td align="char" valign="top" char="." charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Diarrhoea</td><td align="char" valign="top" char="." charoff="50">25</td><td align="char" valign="top" char="." charoff="50">38</td><td align="char" valign="top" char="." charoff="50">22</td><td align="char" valign="top" char="." charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Asthenia</td><td align="char" valign="top" char="." charoff="50">28</td><td align="char" valign="top" char="." charoff="50">20</td><td align="char" valign="top" char="." charoff="50">11</td><td align="char" valign="top" char="." charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Hand&#x02013;foot syndrome</td><td align="char" valign="top" char="." charoff="50">23</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Alopecia</td><td align="char" valign="top" char="." charoff="50">23</td><td align="char" valign="top" char="." charoff="50">54</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Haematological toxicities</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Neutropenia</td><td align="char" valign="top" char="." charoff="50">14</td><td align="char" valign="top" char="." charoff="50">28</td><td align="char" valign="top" char="." charoff="50">26</td><td align="char" valign="top" char="." charoff="50">11</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Febrile neutropenia</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Anaemia</td><td align="char" valign="top" char="." charoff="50">54</td><td align="char" valign="top" char="." charoff="50">26</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Thrombocytopenia</td><td align="char" valign="top" char="." charoff="50">34</td><td align="char" valign="top" char="." charoff="50">5</td><td align="char" valign="top" char="." charoff="50">3</td><td align="char" valign="top" char="." charoff="50">0</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label/><p>NCI-CTC, National Cancer Institute-Common Toxicity Criteria.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">RECIST number of the responder patients</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Patient no.</bold></th><th align="center" valign="top" charoff="50"><bold>Response</bold></th><th align="center" valign="top" char="." charoff="50"><bold>RECIST at baseline</bold></th><th align="center" valign="top" char="." charoff="50"><bold>RECIST at first evaluation</bold></th><th align="center" valign="top" char="." charoff="50"><bold>RECIST at second evaluation</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">103</td><td align="center" valign="top" charoff="50">PR</td><td align="char" valign="top" char="." charoff="50">38</td><td align="char" valign="top" char="." charoff="50">18</td><td align="char" valign="top" char="." charoff="50">20</td></tr><tr><td align="left" valign="top" charoff="50">105</td><td align="center" valign="top" charoff="50">PR</td><td align="char" valign="top" char="." charoff="50">10</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">108</td><td align="center" valign="top" charoff="50">PR</td><td align="char" valign="top" char="." charoff="50">275</td><td align="char" valign="top" char="." charoff="50">230</td><td align="char" valign="top" char="." charoff="50">175</td></tr><tr><td align="left" valign="top" charoff="50">112</td><td align="center" valign="top" charoff="50">PR</td><td align="char" valign="top" char="." charoff="50">114</td><td align="char" valign="top" char="." charoff="50">45</td><td align="char" valign="top" char="." charoff="50">50</td></tr><tr><td align="left" valign="top" charoff="50">113</td><td align="center" valign="top" charoff="50">PR</td><td align="char" valign="top" char="." charoff="50">102</td><td align="char" valign="top" char="." charoff="50">81</td><td align="char" valign="top" char="." charoff="50">25</td></tr><tr><td align="left" valign="top" charoff="50">202</td><td align="center" valign="top" charoff="50">PR</td><td align="char" valign="top" char="." charoff="50">90</td><td align="char" valign="top" char="." charoff="50">90</td><td align="char" valign="top" char="." charoff="50">65</td></tr><tr><td align="left" valign="top" charoff="50">212</td><td align="center" valign="top" charoff="50">PR</td><td align="char" valign="top" char="." charoff="50">78</td><td align="char" valign="top" char="." charoff="50">48</td><td align="char" valign="top" char="." charoff="50">55</td></tr><tr><td align="left" valign="top" charoff="50">205</td><td align="center" valign="top" charoff="50">PR</td><td align="char" valign="top" char="." charoff="50">20</td><td align="char" valign="top" char="." charoff="50">10</td><td align="char" valign="top" char="." charoff="50">10</td></tr><tr><td align="left" valign="top" charoff="50">301</td><td align="center" valign="top" charoff="50">PR</td><td align="char" valign="top" char="." charoff="50">74</td><td align="char" valign="top" char="." charoff="50">48</td><td align="char" valign="top" char="." charoff="50">91</td></tr><tr><td align="left" valign="top" charoff="50">306</td><td align="center" valign="top" charoff="50">PR</td><td align="char" valign="top" char="." charoff="50">80</td><td align="char" valign="top" char="." charoff="50">70</td><td align="char" valign="top" char="." charoff="50">44</td></tr><tr><td align="left" valign="top" charoff="50">308</td><td align="center" valign="top" charoff="50">PR</td><td align="char" valign="top" char="." charoff="50">180</td><td align="char" valign="top" char="." charoff="50">160</td><td align="char" valign="top" char="." charoff="50">118</td></tr><tr><td align="left" valign="top" charoff="50">501</td><td align="center" valign="top" charoff="50">PR</td><td align="char" valign="top" char="." charoff="50">100</td><td align="char" valign="top" char="." charoff="50">90</td><td align="char" valign="top" char="." charoff="50">70</td></tr><tr><td align="left" valign="top" charoff="50">505</td><td align="center" valign="top" charoff="50">PR</td><td align="char" valign="top" char="." charoff="50">50</td><td align="char" valign="top" char="." charoff="50">21</td><td align="char" valign="top" char="." charoff="50">19</td></tr><tr><td align="left" valign="top" charoff="50">803</td><td align="center" valign="top" charoff="50">PR</td><td align="char" valign="top" char="." charoff="50">131</td><td align="char" valign="top" char="." charoff="50">90</td><td align="char" valign="top" char="." charoff="50">78</td></tr><tr><td align="left" valign="top" charoff="50">404</td><td align="center" valign="top" charoff="50">CR</td><td align="char" valign="top" char="." charoff="50">85</td><td align="char" valign="top" char="." charoff="50">35</td><td align="char" valign="top" char="." charoff="50">0</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote2"><label/><p>RECIST, Response Evaluation Criteria in Solid Tumors.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><p content-type="table-title">Results of main published phase II and III studies of irinotecan in previously treated patients with metastatic colorectal cancer</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Reference</bold></th><th align="center" valign="top" charoff="50"><bold>Study phase</bold></th><th align="center" valign="top" charoff="50"><bold><italic>N</italic></bold></th><th align="center" valign="top" charoff="50"><bold>Response rate (&#x00025;)</bold></th><th align="center" valign="top" charoff="50"><bold>Progression-free survival (months)</bold></th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Irinotecan alone after 5FU</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<xref ref-type="other" rid="bib28">Van Cutsem <italic>et al</italic>, 1999</xref></td><td align="center" valign="top" charoff="50">II</td><td align="center" valign="top" charoff="50">107</td><td align="center" valign="top" charoff="50">13.7</td><td align="center" valign="top" charoff="50">4</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<xref ref-type="other" rid="bib18">Pitot <italic>et al</italic>, 1997</xref></td><td align="center" valign="top" charoff="50">II</td><td align="center" valign="top" charoff="50">90</td><td align="center" valign="top" charoff="50">13.3</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<xref ref-type="other" rid="bib19">Rothenberg <italic>et al</italic>, 1999</xref></td><td align="center" valign="top" charoff="50">II</td><td align="center" valign="top" charoff="50">166</td><td align="center" valign="top" charoff="50">11</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<xref ref-type="other" rid="bib20">Rougier <italic>et al</italic>, 1997</xref></td><td align="center" valign="top" charoff="50">II</td><td align="center" valign="top" charoff="50">140</td><td align="center" valign="top" charoff="50">16</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<xref ref-type="other" rid="bib2">Cunningham <italic>et al</italic>, 1998</xref></td><td align="center" valign="top" charoff="50">III</td><td align="center" valign="top" charoff="50">189</td><td align="center" valign="top" charoff="50">&#x02014;</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<xref ref-type="other" rid="bib22">Rougier <italic>et al</italic>, 1998</xref></td><td align="center" valign="top" charoff="50">III</td><td align="center" valign="top" charoff="50">133</td><td align="center" valign="top" charoff="50">5</td><td align="center" valign="top" charoff="50">4.2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<xref ref-type="other" rid="bib7">Fuchs <italic>et al</italic>, 2003</xref></td><td align="center" valign="top" charoff="50">III</td><td align="center" valign="top" charoff="50">291</td><td align="center" valign="top" charoff="50">&#x02014;</td><td align="center" valign="top" charoff="50">3.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Irinotecan combined with LV5FU after 5FU</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<xref ref-type="other" rid="bib5">Ducreux <italic>et al</italic>, 1999</xref></td><td align="center" valign="top" charoff="50">II</td><td align="center" valign="top" charoff="50">55</td><td align="center" valign="top" charoff="50">22</td><td align="center" valign="top" charoff="50">6.3</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<xref ref-type="other" rid="bib8">Gil-Delgado <italic>et al</italic>, 2001</xref></td><td align="center" valign="top" charoff="50">II</td><td align="center" valign="top" charoff="50">39</td><td align="center" valign="top" charoff="50">21</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<xref ref-type="other" rid="bib21">Rougier <italic>et al</italic>, 2002</xref></td><td align="center" valign="top" charoff="50">Randomised phase II</td><td align="center" valign="top" charoff="50">101</td><td align="center" valign="top" charoff="50">11.4</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Irinotecan combined with LV5FU after FOLFOX</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<xref ref-type="other" rid="bib1">Andr&#x000e9; <italic>et al</italic>, 1999</xref></td><td align="center" valign="top" charoff="50">II</td><td align="center" valign="top" charoff="50">33</td><td align="center" valign="top" charoff="50">5.5</td><td align="center" valign="top" charoff="50">4.1</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<xref ref-type="other" rid="bib27">Tournigand <italic>et al</italic>, 2004</xref></td><td align="center" valign="top" charoff="50">III</td><td align="center" valign="top" charoff="50">66</td><td align="center" valign="top" charoff="50">4</td><td align="center" valign="top" charoff="50">2.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<xref ref-type="other" rid="bib13">Mabro <italic>et al</italic>, 2003</xref></td><td align="center" valign="top" charoff="50">II</td><td align="center" valign="top" charoff="50">29</td><td align="center" valign="top" charoff="50">17</td><td align="center" valign="top" charoff="50">4</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<xref ref-type="other" rid="bib15">Maindrault <italic>et al</italic>, 2002</xref></td><td align="center" valign="top" charoff="50">II</td><td align="center" valign="top" charoff="50">20</td><td align="center" valign="top" charoff="50">20</td><td align="center" valign="top" charoff="50">6.7</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;FOLFIRI-3</td><td align="center" valign="top" charoff="50">II</td><td align="center" valign="top" charoff="50">65</td><td align="center" valign="top" charoff="50">23</td><td align="center" valign="top" charoff="50">4.7</td></tr></tbody></table></table-wrap></sec></back></article>


